Hu, Qianqian, Wang, Lujing, Yang, Anne and Lee, Jongbong (2024) Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: A focus on exposure-response analyses. Journal of pharmaceutical sciences, 113 (12). pp. 3434-3446. ISSN 1520-6017

Abstract

Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment by specific targeting of the cancer cells thereby improving the therapeutic window of the drugs. Nevertheless, they are not free from unwanted toxicities mainly resulting from non-specific targeting and release of the payload. Therefore, the dosing regimen must be optimized through integrated analysis of the risk-benefit profile, to maximize the therapeutic potential. Exposure-response (E-R) analysis is one of the most widely used tools for risk-benefit assessment and it plays a pivotal role in dose optimization of ADCs. However, compared to conventional E-R analysis, ADCs pose unique challenges since they feature properties of both small molecules and antibodies. In this article, we review the E-R analyses that have formed the key basis of dose justification for each of the 12 ADCs approved in the USA. We discuss the multiple analytes and exposure metrics that can be utilized for such analysis and their relevance for safety and efficacy of the treatment. For the endpoints used for the E-R analysis, we were able to uncover commonalities across different ADCs for both safety and efficacy. Additionally, we discuss dose optimization strategies for ADCs which are now a critical component in clinical development of oncology drugs.

Item Type:	Article
Keywords:	Humans Immunoconjugates Dose-Response Relationship, Drug Drug Approval Neoplasms Pharmacology, Clinical Risk Assessment Antineoplastic Agents Animals
Date Deposited:	25 Mar 2025 00:45
Last Modified:	25 Mar 2025 00:45
URI:	https://oak.novartis.com/id/eprint/53948